Question 1

Can I switch from Ozempic to Mounjaro?

Accepted Answer

Switching from Ozempic to Mounjaro is straightforward for type 2 diabetes patients. Your clinician will typically wait one week after your last Ozempic dose, then start Mounjaro at the 2.5mg starter dose, even if you were on a higher Ozempic dose. The molecules work differently — semaglutide is a GLP-1 agonist, tirzepatide is a dual GLP-1/GIP agonist — so you titrate Mounjaro from the beginning regardless of Ozempic dose history. SURPASS-2 head-to-head data shows Mounjaro reduces A1C by ~2.3% vs Ozempic ~1.9%. For weight loss switching, switch to Zepbound (same tirzepatide, weight-loss FDA indication) to avoid off-label PA denials.

Question 2

Can I switch from Wegovy to Zepbound?

Accepted Answer

Switching from Wegovy to Zepbound is increasingly common in 2026. Reasons include: Wegovy intolerance (severe GI side effects), weight loss plateau, or insurance coverage loss for Wegovy. Wait one week after final Wegovy dose, then start Zepbound at 2.5mg starter and titrate over 4-week intervals. SURMOUNT-1 trial showed Zepbound delivers ~22% body weight loss vs Wegovy ~15% in SELECT. The OSA-with-obesity FDA indication (December 2024) made Zepbound easier to approve on plans that previously denied weight-loss tirzepatide. LillyDirect cash-pay at $549/month is a backup if insurance denies.

Question 3

Is Zepbound better than Wegovy for weight loss?

Accepted Answer

For pure weight loss, Zepbound (tirzepatide) is statistically superior to Wegovy (semaglutide). SURMOUNT-1 showed ~22% body weight reduction on Zepbound 15mg vs SELECT trial ~15% on Wegovy 2.4mg. The molecules differ — tirzepatide acts on both GLP-1 and GIP receptors, while semaglutide is GLP-1 only. For cardiovascular outcomes, Wegovy has the longer track record — the SELECT trial demonstrated mortality benefit over 5 years. SURPASS-CVOT data for tirzepatide is still maturing. Cash-pay pricing is similar ($549/mo via LillyDirect vs $499/mo via NovoCare). Insurance coverage typically favors Wegovy for weight loss and Zepbound when OSA-with-obesity indication applies.

Question 4

How long do Wegovy side effects last?

Accepted Answer

Wegovy side effects follow a predictable pattern. Nausea, constipation, diarrhea, and sulfur-flavored burps are most intense in the first 4 weeks of starter dose (0.25mg) and during each 4-week dose escalation. Steady-state side effects diminish significantly once you reach maintenance dose (2.4mg) — typically by week 17. ~20% of patients discontinue within first 3 months due to intolerable GI effects. Strategies: take with small low-fat meals, hydrate aggressively, ask your clinician about anti-nausea support (ondansetron) during first month, slow titration if symptoms severe. Severe abdominal pain or persistent vomiting warrants immediate clinician contact — rule out gallstones or pancreatitis.

Question 5

Wegovy vs Zepbound side effects — which is more tolerable?

Accepted Answer

Side effects of Wegovy (semaglutide) and Zepbound (tirzepatide) overlap heavily — nausea, constipation, diarrhea, fatigue, headache. SURMOUNT-1 vs SELECT discontinuation rates are within 1-2 percentage points. Patient reports on Reddit (r/Zepbound, r/WegovyWeightLoss) suggest qualitative differences: Wegovy users describe more "sulfur burps" (a semaglutide-specific finding) while Zepbound users report more fatigue at maintenance doses (10mg+). Tirzepatide users report less food noise but stronger weight-loss effect. If you have severe GI sensitivity, slower titration helps with either drug. If you have a history of pancreatitis, both drugs carry similar warnings.

Question 6

Can I drink alcohol on Wegovy?

Accepted Answer

There is no formal contraindication between Wegovy (semaglutide) and alcohol. However, three real-world effects matter: (1) GLP-1 medications slow gastric emptying, so alcohol absorption is altered — patients report stronger intoxication from smaller amounts; (2) GLP-1s appear to reduce alcohol cravings (an emerging research area in alcohol use disorder treatment); (3) Pancreatitis risk — both heavy alcohol use and GLP-1 medications carry pancreatitis risk, so combination is not advised. Practical guidance: 1-2 drinks occasionally is fine for most. Avoid heavy drinking (more than 3 drinks/day) entirely. Skip alcohol entirely on injection day if you experience strong nausea.

Question 7

Can I exercise on Wegovy?

Accepted Answer

Exercise on Wegovy is not just allowed — it is medically recommended. Without resistance training, ~30-40% of total weight loss on GLP-1 medications comes from lean muscle mass (vs fat). This becomes a long-term metabolic problem if you discontinue Wegovy. Recommendations: (1) Resistance training 2-3x/week is non-negotiable — protect muscle mass; (2) Cardiovascular exercise 150 minutes/week per CDC guidelines, but listen to your body — early-titration fatigue is normal; (3) Hydrate aggressively — GLP-1 dehydration risk is real, especially with high-intensity exercise; (4) Adequate protein intake (1.2-1.6g/kg body weight/day) supports muscle preservation. Many patients report exercise feels harder in first 4-8 weeks; this normalizes by maintenance dose.

Question 8

Who qualifies for Wegovy?

Accepted Answer

Wegovy FDA-approved eligibility: (1) Adult age (≥18); (2) BMI ≥30 (obesity) OR BMI ≥27 with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease; (3) March 2024 expansion: cardiovascular risk reduction in patients with established CVD and overweight/obesity regardless of T2D status. For insurance approval, most plans require 6-12 months of documented diet/exercise failure plus a comorbidity ICD-10 code. Off-label cosmetic weight loss (BMI <27) is not covered and increasingly audited. Pediatric Wegovy is FDA-approved for ages 12-17 with obesity — a separate pathway. Check our coverage matrix for plan-specific PA criteria.

GLP-1s for Cardiovascular event prevention

What the trials show

How prescribers handle it

How coverage works

What we recommend